MRT-8102 for Inflammation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and tolerability of a new oral drug, MRT-8102, which may help reduce inflammation. The study examines how healthy individuals and those at higher risk of heart problems, indicated by elevated CRP (a blood protein signaling inflammation), respond to the drug. Participants may receive either a single dose or multiple doses over several days. Non-smokers who can avoid caffeine meet the eligibility criteria, particularly if they have cardiovascular risk factors with high CRP. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot be on other immunomodulators (drugs that affect the immune system). It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that MRT-8102 is likely to be safe for humans?
Research has shown that MRT-8102 is very safe in early lab studies. It can be administered at doses more than 200 times higher than the expected effective dose in humans without causing harm. This suggests MRT-8102 is likely safe for initial human trials. However, since this marks the first human testing of MRT-8102, the study will closely monitor for any unexpected side effects.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about MRT-8102 because it offers a novel approach to managing inflammation. Unlike traditional treatments that often target symptoms broadly, MRT-8102 is designed to act directly on the inflammation process itself, potentially providing more precise and effective relief. While standard treatments like NSAIDs (nonsteroidal anti-inflammatory drugs) and corticosteroids can come with significant side effects and long-term risks, MRT-8102 aims to minimize these by focusing on a specific mechanism within the inflammatory pathway. This targeted action might also mean quicker results, offering hope for faster symptom relief compared to existing options.
What evidence suggests that MRT-8102 might be an effective treatment for inflammation?
Research shows that MRT-8102 targets a protein called NEK7, which belongs to a group that causes inflammation in the body. By breaking down NEK7, MRT-8102 aims to reduce inflammation. Although this is the first human trial for MRT-8102, it may help treat inflammatory conditions. The trial includes various arms, with participants receiving either MRT-8102 or a placebo, to evaluate its effect on CRP, a marker of inflammation. This could be promising for people with heart health risks.26789
Are You a Good Fit for This Trial?
This trial is for healthy individuals and those at cardiovascular risk with high CRP levels. Participants will be given MRT-8102, an experimental drug, or a placebo to assess safety and determine proper dosing.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Single Dose Treatment
Healthy participants receive a single oral dose of MRT-8102 or placebo
Multiple Dose Treatment (Healthy Participants)
Healthy participants receive multiple oral doses of MRT-8102 or placebo for 7 consecutive days
Multiple Dose Treatment (Cardiovascular Risk Participants)
Participants at cardiovascular risk with elevated CRP receive multiple oral doses of MRT-8102 or placebo for 28 consecutive days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MRT-8102
Find a Clinic Near You
Who Is Running the Clinical Trial?
Monte Rosa Therapeutics, Inc
Lead Sponsor